journal article·2024-05Open access

Combinatorial Screening of Biscarbamate Ionizable Lipids Identifies a Low Reactogenicity Lipid for Lipid Nanoparticle mRNA Delivery

Emily De Lombaerde, Yong Chen, Tingting Ye, Julie Deckers, Giulia Mencarelli, Kim De Swarte, Heleen Lauwers, Ruben De Coen, Sabah Kasmi, Sanne Bevers, Anna Kuchmiy, Bram Bogaert, Lies Baekens, Zifu Zhong, Alexander Lamoot, Niek N. Sanders, Bart N. Lambrecht, Antonio P. Baptista, Stefaan De Koker, Bruno G. De Geest

Advanced Functional Materials· Volume 34· Issue 21

Abstract

Abstract Messenger RNA (mRNA) has emerged as a promising therapeutic modality for various diseases. However, efficient delivery of mRNA into target cells remains a significant challenge. In this study, the combinatorial synthesis and characterization of a novel series of ionizable biscarbamate lipids (IBLs) for mRNA lipid nanoparticle (LNP) delivery are reported. A simplified and scalable method is developed, resulting in IBLs suitable for formulating mRNA into stable LNPs. Two generations of IBLs are synthesized and evaluated for their mRNA transfection capacity in vitro, using eGFP as a reporter protein, leading to the identification of S‐Ac7‐DOG as a lead IBL. Upon intramuscular vaccination, S‐Ac7‐DOG LNPs instigated robust antigen‐specific CD8+ T cell responses against an mRNA encoded viral oncoprotein and a tumor neo‐antigen. In comparison to MC3 LNPs, which are used as a benchmark, S‐Ac7‐DOG LNPs exhibit low reactogenicity, robust mRNA transfection, and a distinct biodistribution, with higher accumulation in draining lymph nodes and spleen. These findings highlight the potential of IBLs as a novel and promising class of ionizable lipids for mRNA delivery in vaccines and beyond.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics Ghent University Ghent 9000 Belgium

Laboratory of Mucosal Immunology VIB‐UGent Center for Inflammation Research Ghent University Ghent 9052 Belgium

Department of Internal Medicine and Pediatrics Faculty of Medicine and Health Sciences Ghent University Ghent 9000 Belgium

Department of Experimental Medicine and Biochemical Sciences University of Perugia Perugia 06132 Italy

etherna Niel 2845 Belgium

Laboratory of Gene Therapy Department of Veterinary and Biosciences Faculty of Veterinary Medicine Ghent University Merelbeke 9820 Belgium

Funding

H2020 European Research Council

References (54)

Show source-provided references
1. Li Y. · Front. Bioeng. Biotechnol. · 2022 · 10
2. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
3. 10.3390/vaccines1103065810.3390/vaccines11030658 ↗
4. 10.3390/vaccines901006510.3390/vaccines9010065 ↗
5. 10.1038/nrd.2017.24310.1038/nrd.2017.243 ↗
6. 10.1038/s41587-022-01491-z10.1038/s41587-022-01491-z ↗
7. 10.1021/acs.bioconjchem.0c0036610.1021/acs.bioconjchem.0c00366 ↗
8. 10.3389/fbioe.2021.64670810.3389/fbioe.2021.646708 ↗
9. 10.1038/nature1830010.1038/nature18300 ↗
10. 10.3389/fchem.2020.58995910.3389/fchem.2020.589959 ↗
11. 10.1016/j.ymthe.2017.03.01310.1016/j.ymthe.2017.03.013 ↗
12. 10.3390/ijms2403270010.3390/ijms24032700 ↗
13. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
14. 10.1002/btm2.1021310.1002/btm2.10213 ↗
15. 10.1038/s42003-021-02441-210.1038/s42003-021-02441-2 ↗
16. 10.1016/j.tips.2021.03.00210.1016/j.tips.2021.03.002 ↗
17. 10.1016/j.addr.2022.11441610.1016/j.addr.2022.114416 ↗
18. 10.3389/fcell.2021.71018610.3389/fcell.2021.710186 ↗
19. 10.3390/nano1002036410.3390/nano10020364 ↗
20. 10.1016/j.nantod.2018.10.00510.1016/j.nantod.2018.10.005 ↗
21. Moderna. Patent WO2017049245A2. Compounds and compositions for intracellular delivery of therapeutic agents2017.
22. 10.1021/acs.accounts.1c0050010.1021/acs.accounts.1c00500 ↗
23. 10.1038/s41587-019-0247-310.1038/s41587-019-0247-3 ↗
24. 10.1039/D3TB00649B10.1039/D3TB00649B ↗
25. 10.1016/j.omtn.2019.01.01310.1016/j.omtn.2019.01.013 ↗
26. 10.3390/molecules2706194310.3390/molecules27061943 ↗
27. 10.1038/mt.2013.12410.1038/mt.2013.124 ↗
28. 10.1038/s41587-023-01679-x10.1038/s41587-023-01679-x ↗
29. 10.1002/adma.20220962410.1002/adma.202209624 ↗
30. 10.1021/acsnano.6b0232610.1021/acsnano.6b02326 ↗
31. 10.1038/nbt.418110.1038/nbt.4181 ↗
32. 10.1021/acsami.7b1598210.1021/acsami.7b15982 ↗
33. 10.1002/anie.20110088410.1002/anie.201100884 ↗
34. 10.1021/jacs.2c1067010.1021/jacs.2c10670 ↗
35. 10.1021/acs.molpharmaceut.2c0003310.1021/acs.molpharmaceut.2c00033 ↗
36. 10.1016/j.addr.2016.01.02210.1016/j.addr.2016.01.022 ↗
37. 10.1038/s41563-020-00886-010.1038/s41563-020-00886-0 ↗
38. 10.1002/smll.20220696810.1002/smll.202206968 ↗
39. 10.1016/j.cis.2017.12.00610.1016/j.cis.2017.12.006 ↗
40. Holmquist M. · Curr. Protein Pept. Sci. · 2000 · 9 · 732
41. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
42. 10.1007/s12274-018-2091-z10.1007/s12274-018-2091-z ↗
43. 10.1038/s41596-022-00755-x10.1038/s41596-022-00755-x ↗
44. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
45. 10.1038/s41598-017-02831-910.1038/s41598-017-02831-9 ↗
46. 10.1038/s41598-020-62448-310.1038/s41598-020-62448-3 ↗
47. 10.1016/j.ymthe.2022.07.00710.1016/j.ymthe.2022.07.007 ↗
48. 10.1021/acsnano.8b0096610.1021/acsnano.8b00966 ↗
49. 10.1038/s41416-020-01048-410.1038/s41416-020-01048-4 ↗
50. 10.1158/2326-6066.CIR-13-022310.1158/2326-6066.CIR-13-0223 ↗
51. 10.1038/s41586-023-06063-y10.1038/s41586-023-06063-y ↗
52. 10.1038/nature1400110.1038/nature14001 ↗
53. 10.1038/s41467-019-11321-710.1038/s41467-019-11321-7 ↗
54. 10.1016/j.addr.2020.06.00210.1016/j.addr.2020.06.002 ↗